Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

Date

21 Oct 2023

Session

Poster session 07

Topics

Tumour Immunology;  Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Nicolas Huyghe

Citation

Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. 10.1016/S0923-7534(23)01927-0

Authors

N. Huyghe1, E. Benidovskaya1, T. Masoodi2, J. Carrasco3, A. De Cuyper4, I. Sinapi3, F. Vempalli2, E. Verstraelen5, P. Goffette5, B. Ghaye5, M. Papier3, D. Bedognetti2, A. van Maanen5, M. Castella5, J. Galon6, M. van den Eynde4

Author affiliations

  • 1 Irec Miro Onco, UCLouvain - Université Catholique de Louvain, 1200 - Woluwe-Saint-Lambert/BE
  • 2 Sidra, Sidra Medical and Research Center, Al-Rayyan/QA
  • 3 Medical Oncology Department, GHdC - Grand Hopital de Charleroi - Site Notre Dame, 6000 - Charleroi/BE
  • 4 Digestive Oncology Department, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), 1200 - Woluwe-Saint-Lambert/BE
  • 5 Saint Luc, Institut Roi Albert II - Cliniques universitaires St-Luc, 1200 - Brussels/BE
  • 6 Cordeliers Research Center, Inserm Team 15, Laboratory of Integrative Cancer Immunology, 75006 - Paris/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2237P

Background

This trial explores the clinical efficacy and safety of AVE, CET and IRI for treatment refractory MSS mCRC. We aim at characterizing the immune response for biomarker discovery through associated translational research.

Methods

MSS, chemorefractory (anti-EGFR refractory if RAS wt) mCRC patients (pts) were enrolled (RAS wt: 28 pts, RAS mut: 27 pts) and treated with CET and IRI from week 1(W1) and AVE from W3. Clinical objectives (safety, tumor response, disease control rate (DCR), PFS and OS) were presented separately. Exploratory endpoints include predictive efficacy biomarkers (immunoscore (IS), immune tumor microenvironment, gene expression profile (GEP), ctDNA) and modification overtime. Multiplex immunofluorescence (MIF), RNAseq and ctDNA analyses were done (sequential metastasis biopsies and plasma samples at W0, W3, W11). CD3, CD8, CD45RO, PD1, PD-L1cells densities were quantified. RNA-seq data were used to perform several analyses (DESeq2, GSEA, deconvolution, gene ontology). OncoSELECT panel (58 genes) was used to follow ctDNA variation over time (mean variant allele frequency).

Results

Among 55 treated pts, 95 biopsies (W0: 39, W3: 29, W11: 27) were available for MIF (table: W0 results). On 23 pts (1st stage), upregulation of adaptive immune response signature was associated with tumor shrinkage, PFS>6 and OS>12 months (p. adj= 0.00). Few modifications of immune cells and GEP were observed overtime (W0, W3, W11). ctDNA decrease (>10%) was associated with tumor response (p=0.04) and PFS (6.6 vs 3.4 months, p=0.08). Table: 2237P

Characteristics IS (CD3/CD8) high CD3/PD1 high CD3/CD8/CD45RO/PD1 high
High/others:pts 10/29 10/29 8/31
RAS-wt/RAS-mut:OR, p-v 1.39, p=0.73 0.82, p=0.99 0.83, p=0.99
Tumor shrinkage: OR, p-v 8.32, p=0.00 4.50, p=0.05 9.54, p=0.00
DCR:OR, p-v 8.02, p=0.05 3.16, p=0.26 5.55, p=0.12
PFS:HR, p-v 0.29, p=0.00 0.28, p=0.00 0.43, p=0.03
OS:HR, p-v 0.62, p=0.19 0.26, p=0.00 0.47, p=0.06

Conclusions

Independently of RAS mutation, existing adaptive immune response within metastases is associated with treatment benefit. ctDNA decrease is associated with tumor response.

Clinical trial identification

NCT03608046.

Editorial acknowledgement

Legal entity responsible for the study

Cliniques Universitaires Saint-Luc (Pr. MD. PhD. Marc van den Eynde).

Funding

Merck Serono.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.